Targeted therapy for lung cancer using Apatinib.

Lung Cancer Breakthrough: Can Apatinib Offer New Hope for Advanced Squamous Cell Carcinoma?

Author's portrait.
Samir D’Costa in Health & Wellness May 2025 • 4 min read.

"Explore how low-dose Apatinib monotherapy is emerging as an effective treatment for advanced lung squamous cell carcinoma, offering a new perspective on managing this challenging disease."


Lung cancer remains a leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Among NSCLC subtypes, squamous cell carcinoma (SqCC) presents unique challenges in treatment, especially in advanced stages where chemotherapy options become limited.

Traditional chemotherapy regimens often serve as the first line of defense, but when the disease progresses, finding effective second-line treatments becomes crucial. This is where targeted therapies and novel approaches come into play, offering new hope for patients facing advanced SqCC.

Apatinib, a small molecule inhibitor targeting vascular endothelial growth factor receptor-2 (VEGFR-2), has shown promise in treating advanced NSCLC. Recent studies explore its efficacy and safety, particularly at lower dosages, providing new insights into managing advanced lung SqCC. This article delves into the potential of Apatinib monotherapy, examining its impact, benefits, and considerations for patients and healthcare professionals.

Apatinib: A New Monotherapy Option for Lung Squamous Cell Carcinoma?

Targeted therapy for lung cancer using Apatinib.

A recent study published in the Journal of Thoracic Oncology explored the effectiveness of low-dose Apatinib monotherapy in treating advanced lung squamous cell carcinoma. The study aimed to assess whether Apatinib, a VEGFR-2 inhibitor, could offer a viable treatment option for patients who had exhausted other lines of chemotherapy or were unsuitable candidates for traditional regimens.

The study enrolled 19 patients with definitive diagnoses of SqCC, all of whom had either refused chemotherapy or had experienced treatment failure with prior lines of therapy. The key exclusion criteria included significant blood vessel involvement and severe hemoptysis, ensuring the safety and suitability of participants for the Apatinib treatment. The results showed promising outcomes, highlighting Apatinib's potential as a monotherapy option. Key findings included:
  • Objective Response Rate (ORR): 17.6% (3/17 patients) achieved partial response.
  • Disease Control Rate (DCR): 76.5% (13/17 patients) experienced disease control.
  • Median Progression-Free Survival (PFS): 5.3 months (95% CI: 2.7-7.9 months).
  • One-Year Survival Rate: 21.1% (4/19 patients).
These results indicate that Apatinib monotherapy can provide meaningful clinical benefits for patients with advanced lung SqCC, particularly those who have limited treatment options. The disease control rate suggests that Apatinib effectively stabilizes the disease, while the progression-free survival offers a reasonable duration of benefit. Furthermore, the one-year survival rate provides a benchmark for overall survival improvement.

Looking Ahead: Validating Apatinib's Role in Lung Cancer Treatment

Apatinib monotherapy at a lower dosage presents a potentially valuable option for patients with advanced lung squamous cell carcinoma, especially when other treatments have failed or are not suitable. These findings suggest that Apatinib can offer a meaningful clinical benefit by controlling disease progression and improving survival rates. Further research, including larger clinical trials, is essential to validate these results and fully understand the role of Apatinib in lung cancer treatment.

Related Articles

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.